LAROSA JOSEPH J 4
4 · REGENERON PHARMACEUTICALS, INC. · Filed Dec 9, 2025
Insider Transaction Report
Form 4
LAROSA JOSEPH J
SVP Gen Counsel and Secretary
Transactions
- Award
Common Stock
2025-12-05+2,476→ 30,913 total - Tax Payment
Common Stock
2025-12-08$712.94/sh−1,396$995,264→ 29,517 total - Award
Non-Qualified Stock Option (right to buy)
2025-12-05+12,210→ 12,210 totalExercise: $726.71Exp: 2035-12-05→ Common Stock (12,210 underlying)
Holdings
- 3,402(indirect: By 2024 GRAT)
Common Stock
- 9,000(indirect: By 2025 GRAT)
Common Stock
- 396(indirect: By 401(k))
Common Stock
Footnotes (2)
- [F1]Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 5, 2027 and 50% on December 5, 2029.
- [F2]The stock option award vests in four equal annual installments, commencing one year after the date of grant.